Does Medicare cover Zepbound or Wegovy?
Not for weight loss, and the reason is statutory rather than a plan decision: the Social Security Act excludes agents used for weight loss from the Part D benefit. Everything below is about the routes around that exclusion, and each one is a different indication rather than a different plan.
Does Medicare cover Zepbound or Wegovy?
Medicare is not one plan either, but it is the one payer whose rules come from statute rather than from an employer's choice — which makes it the only one on this site with a definite answer. halfrx publishes no coverage verdict for Medicare, because there is no single one that would be true for most readers — and a page that states one confidently is wrong for everybody it does not fit. The document that settles it is the drug list attached to your specific plan. What is knowable is the shape of the criteria where coverage exists: a BMI threshold, usually 30 or 27 with a weight-related condition, prior authorisation, and often a requirement to try a cheaper drug first. If the answer is no, that is a price question rather than a coverage one: the cheapest verified cash route on this site is Compounded semaglutide at $199 a month, checked against the seller's own page on 2026-06-10, and paying cash does not touch a deductible. The indication written on the prescription decides more than the plan does — sleep apnea and cardiovascular risk are separate FDA labels, and an exclusion written against weight loss does not reach them.
What is actually knowable
Part D excludes weight-loss drugs by statute
Section 1927(d)(2) of the Social Security Act lists drugs used for weight loss among those a plan may exclude, and Part D adopted that exclusion. CMS has proposed reinterpreting it to recognise obesity as a chronic disease; until that lands, a Part D plan cannot cover a GLP-1 prescribed for weight alone no matter how the paperwork is written.
The Medicare GLP-1 Bridge runs 1 July 2026 to 31 December 2027, at $50 a month
A CMS demonstration under Section 402 authority, not a Part D benefit. It covers all formulations of Foundayo and Wegovy and the KwikPen formulation of Zepbound, for Part D beneficiaries whose prescriber submits a prior authorisation attesting the drug treats obesity. The catch is structural: because it sits outside Part D, the $50 counts toward neither your deductible nor the out-of-pocket maximum.
A different indication is covered, and it is the route most people miss
The exclusion is about the indication, not the molecule. Semaglutide for type 2 diabetes, Wegovy for cardiovascular risk reduction, and Zepbound for moderate to severe obstructive sleep apnea are all coverable under Part D because none of them is 'used for weight loss' in the statute's sense. If one of those applies to you, the question at a denial is which indication was written, not whether Medicare covers the drug.
Manufacturer copay cards cannot be used with Medicare at all
Federal anti-kickback rules bar a manufacturer from subsidising a copay inside a federal health programme. Every '$25 card' in this category says 'commercially insured' for that reason, and it is why the Bridge exists as a separate route rather than as a card.
How to get your own answer
- 1Check which indication your prescription was written under. That single line decides more than the plan does.
- 2If it is obesity alone, check eligibility for the GLP-1 Bridge — it is the only route CMS currently offers for that indication.
- 3Look up your specific Part D plan's formulary for the diabetes, cardiovascular or sleep-apnea indication if one applies to you.
Then take the criterion it gives you to the prior authorisation pack or, at a denial, the appeal letter builder. Both run entirely in your browser and send nothing anywhere.
If the answer is no, this is the price
Cheapest verified cash routes, each read from the seller's own page. Paying cash does not touch a deductible or an out-of-pocket maximum — which cuts both ways.
| Route | A month | What it is | Checked |
|---|---|---|---|
| Compounded semaglutide | $199 | compounded, not FDA approved | 2026-06-10, past the 45-day window |
| Ozempic | $199 | branded, FDA approved | 2026-06-10, past the 45-day window |
| Compounded tirzepatide | $200 | compounded, not FDA approved | 2026-06-10, past the 45-day window |
| Foundayo | $299 | branded, FDA approved | 2026-08-20 |
Medicare coverage, answered
- Does Medicare cover Zepbound?
- Medicare is not one plan either, but it is the one payer whose rules come from statute rather than from an employer's choice — which makes it the only one on this site with a definite answer. The page above lists what is actually knowable and names the document that settles it for one specific plan. halfrx publishes no coverage verdict for Medicare because there is no single one to publish, and a confident answer here would be wrong for most readers.
- Will Medicare start covering weight-loss drugs?
- CMS has proposed reinterpreting the statutory exclusion to treat obesity as a chronic disease. Proposed is not in force, and this page will say so until it changes. The Bridge demonstration was extended by a year rather than replaced, which is a signal about timing rather than a promise.
- What if the answer is no?
- Paying cash is a separate transaction with its own price, and it does not touch a deductible. The cheapest verified route on this site is Compounded semaglutide at $199 a month, read from the seller's own page on 2026-06-10. Every route with a verified price is ranked at /c.
halfrx does not state whether Medicare covers a drug for you, because coverage is set per plan and a confident answer would be wrong for most readers. Everything above is either a structural fact about how this payer works or a quotation from a document linked beside it, with its scope stated. Information only, not medical or insurance advice.